) recently announced that the U.S. Food and Drug Administration
(FDA) has cleared its quadrivalent formulation of intramuscular
Flulaval. Flulaval Quadrivalent has been approved for the
prevention of influenza caused by types A and B strains in adults
and children aged 3 years and above.
Flulaval Quadrivalent helps fight against two strains of
influenza A and two strains of influenza B, thus providing it
with an edge over the currently available trivalent Flulaval
version, which is only approved for use in adults. We expect the
approval of Flulaval Quadrivalent to enable the company to
solidify its position in the market once it is made available
We note that this is the second intramuscular quadrivalent
influenza vaccine in Galxo's portfolio. In Dec 2012, the FDA
approved Fluarix Quadrivalent for treating adults and children
aged 3 years and above. The intramuscular vaccine is now
available to the customers.
Currently approved quadrivalent influenza vaccines include
) intranasal influenza vaccine FluMist Quadrivalent and
) quadrivalent formulation of Fluzone.
Glaxo currently holds a Zacks Rank #3 (Hold). The biggest
near-term challenge for Glaxo will be to replace the revenues
that will be lost to generic competition. Products like Valtrex,
Lamictal, Imitrex, Requip, Combivir and Epivir are already facing
declining sales due to intense generic competition.
Going forward, a major part of Glaxo's revenues will be
exposed to generic competition, as products like Pandemrix and
Prepandrix are scheduled to lose exclusivity in the next few
ACTELION LTD (ALIOF): Get Free Report
ASTRAZENECA PLC (AZN): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
We believe that the pipeline at Glaxo must deliver to counter the
generic threat. We are impressed by Glaxo's growth-by-acquisition
strategy to combat the loss of revenues due to genericization of
Meanwhile, stocks such as
) currently look more attractive in the pharma space with a Zacks
Rank #1 (Strong Buy).